By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Specialised Therapeutics Australia 

P.O. Box 250

East Kew  Victoria  3102  Australia
Phone: 1300-798-820 Fax: 1800-798-829


Company News
Specialised Therapeutics Australia Release: Australian PBS Listing For New Drug To Treat Chronic Myeloid Leukaemia - Iclusig 11/2/2015 10:10:43 AM
Specialised Therapeutics Australia' Breakthrough Brain Tumour Visualisation Drug GLIOLAN Approved For Use In New Zealand 9/18/2015 6:04:13 AM
Specialised Therapeutics Australia Release: Cutting Edge Breast Cancer Test "Should Be Reimbursed" - Medical Experts 9/3/2015 9:29:48 AM
Specialised Therapeutics Australia Release: TGA Approves AKYNZEO(R) (netupitant/palonosetron) For The Prevention Of Chemotherapy-Induced Nausea And Vomiting (CINV) 5/8/2015 6:22:07 AM
Ariad Pharmaceuticals, Inc. (ARIA) And Specialised Therapeutics Australia Announce Approval Of Iclusig (Ponatinib) In Australia 11/24/2014 9:38:04 AM
Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) To Be PBS Listed For Metastatic Pancreatic Cancer 10/31/2014 8:25:27 AM
Alimera Sciences (ALIM) Signs Specialised Therapeutics Australia As Exclusive Iluvien® Distributor For Australia, New Zealand 4/28/2014 9:22:12 AM
Specialised Therapeutics Australia Receives Therapeutic Goods Administration Approval for Brain Tumour Visualisation Drug - Gliolan® 11/11/2013 10:55:23 AM
Specialised Therapeutics Australia Release: ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients 10/25/2012 10:44:05 AM
Optimer Pharmaceuticals, Inc. (OPTR) and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand 6/19/2012 11:52:53 AM